Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Almac, Affymetrix In Global Xcel Array Distribution Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Almac, Affymetrix In Global Xcel Array Distribution Pact

Assay aims to accelerate personalized medicine opportunities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Almac and Affymetrix have signed an exclusive global distribution agreement allowing Affymetrix to sell Almac’s Xcel Array for biomarker discovery, development and delivery worldwide.
 
The Xcel array is a high-density transcriptome-based microarray that has been optimized for the discovery and development of biomarkers from formalin fixed paraffin embedded (FFPE) tissue. The array contains more than 97,000 transcripts including antisense, non-coding transcripts and significant unique content. Working with FFPE enables the potential to profile retrospective samples in tissue banks for potential discovery opportunities in personalized medicine.  
 
Michael Sloan, vice president of business development of Almac’s Diagnostics Business Unit, said, “We are very pleased to have entered into this agreement with Affymetrix. The Xcel array has proven to be extremely useful in our hands for biomarker discovery both for our in-house R&D and for our clients. This distribution deal with Affymetrix will enable more researchers to see the benefit of the platform.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics